Remove Capital Remove Funding Remove Pricing Remove San Diego
article thumbnail

TuSimple Prices IPO, Starts Trading Today

socalTECH

San Diego-based TuSimple priced its IPO last night, saying that it will sell 33,783,783 shares of its Class A common stock at the price of $40.00 Morgan, along withBofA Securities, Cowen, Credit Suisse, Nomura and RBC Capital Markets, Baird, Needham & Company, Oppenheimer & Co., Piper Sandler and Valuable Capital.

Pricing 113
article thumbnail

San Diego's Seismic Snags $100M, Joins Unicorns

socalTECH

San Diego-based Seismic , a developer of sales and marketing software, has raised $100M more in a funding round, which values the company at $1 billion, the company said on Tuesday. The funding round came from Lightspeed Venture Partners, T. Rowe Price, plus General Atlantic, JMI Equity, and Jackson Square Ventures.

San Diego 113
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Odonate Therapeutics Prices IPO

socalTECH

San Diego-based Odonate Therapeutics , a pharmaceuticals startup focused on chemotherapy drugs, has priced its IPO, saying on Wednesday afternoon that it has priced its IPO at $24.00 per share was on the low end of its initial estimated pricing range of $24.00 The $24.00 READ MORE>>.

Pricing 113
article thumbnail

Arena Pharmaceuticals Spins Off Longboard Pharmaceuticals With $56M Funding

socalTECH

San Diego-based Arena Pharmaceuticals announced this morning that it has launched a new company, Longboard Pharmaceuticals , with $56M in funding. The new funding comes from Farallon Capital, Cormorant Asset Management, HBM Healthcare Investments, Highside Capital Management, and T.

Funding 113
article thumbnail

Avidity Biosciences Ups Public Offering Size

socalTECH

San Diego-based biopharmaceuticals company Avidity Biosciences said on Thursday that it has upsized its public offering, and will be offering up 12,000,000 shares of its common stock at a price to the public of $17.25 per share, and is now expecting to raise $207M for the company. The company is working on RNA therapeutics.

San Diego 113
article thumbnail

San Diego Life Sciences Roundup: Evofem, Cullgen, BrainLeap & More

Xconomy

Locally based biotech companies receive fresh funding from investors. Get the details on these developments and more in San Diego life sciences news: —Evofem Biosciences (NASDAQ: EVFM ) struck a deal to raise up to $80 million in a private placement. million shares.

article thumbnail

Design Therapeutics Picks Up $125M For Small Molecules

socalTECH

San Diego-based Design Therapeutics, a biotech company which is developing small molecules for the treatment of serious degenerative disorders caused by inherited nucleotide repeat expansions, said it has raised $125M in its Series B funding round. Rowe Price Associates, Inc., Arsani William, M.D.,

Design 113